Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Dow
Mallinckrodt
Cantor Fitzgerald
Julphar
Queensland Health
Express Scripts
QuintilesIMS
Cerilliant

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,984,403

« Back to Dashboard

Which drugs does patent 6,984,403 protect, and when does it expire?

Patent 6,984,403 protects ZMAX and is included in one NDA.

This patent has forty-six patent family members in forty-three countries.
Summary for Patent: 6,984,403
Title:Azithromycin dosage forms with reduced side effects
Abstract:The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
Inventor(s): Hagen; Timothy A. (East Lyme, CT), Lo; Julian B. (Old Lyme, CT), Thombre; Avinash G. (East Lyme, CT), Herbig; Scott M. (East Lyme, CT), Appel; Leah Elizabeth (Bend, OR), Crew; Marshall David (Bend, OR), Friesen; Dwayne Thomas (Bend, OR), Lyon; David Keith (Bend, OR), McCray; Scott Baldwin (Bend, OR), West; James Blair (Bend, OR)
Assignee: Pfizer Inc. (New York, NY)
Application Number:10/763,340
Patent Claim Types:
see list of patent claims
Dosage form; Use; Composition;

Drugs Protected by US Patent 6,984,403

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pf Prism Cv ZMAX azithromycin FOR SUSPENSION, EXTENDED RELEASE;ORAL 050797-001 Jun 10, 2005 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING BACTERIAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,984,403

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2218 ➤ Sign Up
Argentina 045630 ➤ Sign Up
Austria 407663 ➤ Sign Up
Australia 2004216676 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cerilliant
US Department of Justice
Covington
Express Scripts
Harvard Business School
Federal Trade Commission
Teva
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.